Back to Search Start Over

Salarius Announces Publication of Scientific Paper Highlighting Potential of Combining Seclidemstat with Checkpoint Inhibitors

Source :
Legal Monitor Worldwide. February 5, 2020
Publication Year :
2020

Abstract

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by mis-regulated gene expression, today announced the publication of a scientific paper entitled, The Novel Reversible LSD1 Inhibitor [...]

Details

Language :
English
Database :
Gale General OneFile
Journal :
Legal Monitor Worldwide
Publication Type :
News
Accession number :
edsgcl.613531598